Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system

OBJECTIVE: In 2017, the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) introduced a standardised process to appraise innovativeness of medicines. Innovative medicines are provided speeder market access and dedicated funds. Innovativeness criteria are: unmet therapeutic need, added the...

Descripción completa

Detalles Bibliográficos
Autores principales: Galeone, Carlotta, Bruzzi, Paolo, Jommi, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812109/
https://www.ncbi.nlm.nih.gov/pubmed/33441356
http://dx.doi.org/10.1136/bmjopen-2020-041259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812109/
https://www.ncbi.nlm.nih.gov/pubmed/33441356
http://dx.doi.org/10.1136/bmjopen-2020-041259

Ejemplares similares